Xpention Genetics

Xpention is a pre-clinical stage biotechnology company pioneering a novel class of delivery vehicles for large genetic medicines. The company's proprietary Xpention platform utilizes exogenous protein-mediated encapsidation to deliver large genetic payloads, including full-length genes and advanced gene-editing tools like prime editors, which exceed the capacity of traditional viral vectors. By overcoming these size limitations, Xpention aims to expand the reach of genomic medicines to a broader range of genetic diseases that were previously difficult to target. The company was co-founded by renowned gene-editing pioneer Dr. David Liu and Dr. Samagya Banskota, leveraging foundational research from the Broad Institute and Harvard University. Xpention is headquartered in Cambridge, Massachusetts, and is backed by a syndicate of leading life sciences investors.